We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Data-Driven Testing Strategy Could Enable Fast Turnaround of COVID-19 Test Results for Healthcare Workers

By LabMedica International staff writers
Posted on 27 Apr 2021
A new methodology for testing pooled samples that maximizes the proportion of samples resolved after a single round of testing can speed up COVID-19 test results for healthcare workers.

Investigators at University of Manchester (Manchester, UK) have developed a COVID-19 testing strategy that maximizes the proportion of negative results after a single round of testing, allowing prompt notification of results. More...
The method also reduces the need for increasingly limited test reagents, as fewer additional tests are required.

Fast turnaround of COVID-19 test results for healthcare workers is critical. There is an urgent need to reduce the spread of COVID-19 transmission in hospitals and care facilities and to maintain adequate levels of staffing. Group testing strategies with pooled samples have been proposed to increase capacity; however, the currently used strategies are slow.

Traditional Dorfman sequential (DS) pooling combines multiple samples and, if a pool test returns positive, all of the constituent samples undergo further testing. In a healthcare setting, this means that even individuals who ultimately test negative for COVID-19 will have to isolate. The investigators developed a non-adaptive combinatorial (NAC) pooling approach that tests the same sample in several simultaneously assayed pools. The algorithm assumes initially that each sample is positive. It then attempts to disprove this assumption by finding a well in which the sample has been placed that has tested as negative. Then another algorithm is used to find positive wells that contain a single sample on the list of the remaining potentially positive samples. Indeterminate samples are retested.

To establish a suitable limit of detection for pooling, nasopharyngeal samples of known SARS-CoV-2 status were placed in two pools, each containing 14 SARS-CoV-2 negative samples and one SARS-CoV-2 positive sample, with the positive samples at differing viral loads. Pooling matrices were generated for 700, 350, and 250 samples, with each sample assigned to 2, 4, and 5 wells, respectively. The samples were also tested in a DS testing scheme. The efficacy of each matrix was tested under different SARS-CoV-2 prevalence levels of 0.1%, 3%, 7%, and 10% of the population.

All NAC matrices performed well at low prevalence levels, with an average of 585 tests saved per assay in the 700 sample matrix. In simulations of low-to-medium prevalence levels (0.1% – 3%), which is the prevalence expected in an asymptomatic healthcare worker population, all the NAC matrices required fewer retests than the DS testing scheme. However, as the population prevalence increased, the performance of each matrix deteriorated. The matrices and system to decode the results are freely available and laboratories can choose the matrix that best suits their current population prevalence and sample size, facilitating a context-specific, relatively low cost data-driven testing approach.

“Using the method we have developed, any laboratory could adapt their testing scheme based on the current throughput and the current prevalence of infection in the population, facilitating a data-driven testing strategy,” explained lead investigators Graeme Black, DPhil, and John Henry McDermott, MD, both from the Division of Evolution and Genomic Sciences, School of Biological Sciences, University of Manchester, Manchester, UK. “Many high-throughput testing schemes for SARS-CoV-2 detection have been developed over the past year. We illustrate the potential power that adaptable automated, innovative mathematical approaches have to increase COVID-19 diagnostic capability in a safe manner. Such an approach could reach far greater numbers, save lives, and be delivered in a sustainable way. Undoubtedly, this has considerable relevance to other future population-based screening approaches.”

Related Links:
University of Manchester


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.